Monday, 6 January 2020

Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis - P&T Community

Protagonist Therapeutics Initiates Phase 2 Study of Novel Hepcidin Mimetic PTG-300 in the Treatment of Patients with Hereditary Hemochromatosis  P&T Community

from "phlebotomist" - Google News http://bit.ly/2Qs7tt5

No comments:

Post a Comment